Table 2 Evidence profile
Certainty assessment | No. of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TXA | Placebo | Relative (95% CI) | Absolute (95% CI) | ||
Mortality from any cause (low RoB) | ||||||||||||
4 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 883/4940 (17.9%) | 936/4844 (19.3%) | RR 0.93 (0.85 to 1.01) | 14 fewer per 1000 (from 29 fewer to 2 more) | High ⊕⊕⊕⊕ | Critical |
Poor neurological outcome (low RoB) | ||||||||||||
3 | Randomized trials | Not serious | Not serious | Not serious | Seriousa | None | 52/313 (16.6%) | 67/306 (21.9%) | RR 0.76 (0.55 to 1.06) | 53 fewer per 1000 (from 99 fewer to 13 more) | Moderate ⊕⊕⊕〇 | Critical |
Ischemic or thromboembolic complications (low RoB) | ||||||||||||
2 | Randomized trials | Not serious | Seriousb | Not serious | Very seriousc | None | 69/4733 (1.5%) | 63/4632 (1.4%) | RR 0.68 (0.12 to 3.93) | 4 fewer per 1000 (from 12 fewer to 40 more) | Very low ⊕〇〇〇 | Critical |
Hemorrhagic complications (bleeding, low RoB) | ||||||||||||
1 | Randomized trials | Not serious | Not serious | Not serious | Very seriousc | None | 16/4613 (0.3%) | 22/4514 (0.5%) | RR 0.71 (0.37 to 1.35) | 1 fewer per 1000 (from 3 fewer to 2 more) | Low ⊕⊕〇〇 | Critical |